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Background: Enhanced inflammatory host responses have been attributed as the cellular basis for development of
severe malaria as well as sepsis. In contrast to this, filarial infections have been consistently reported to be
associated with an immunological hypo-responsive phenotype. This suggests that successful control of filariasis by
employing mass drug administration, could potentially contribute to an increase in incidence of sepsis and cerebral
malaria in human communities. A case control study was undertaken to address this critical and urgent issue.
Methods: Eighty-nine patients with sepsis and one hundred and ninety-six patients with P. falciparum malaria all
originating from Odisha, were tested for prevalence of circulating filarial antigens - a quantitative marker of active
filarial infection. Antibodies to four stage specific malarial recombinant proteins were measured by solid phase
immunoassays and circulating CD4+CD25high T-cells were quantified by flow cytometry with an objective to study if
pre-existing filarial infections influence antibody responses to malarial antigens or the levels of circulating T-
regulatory cells in P. falciparum infected patients.
Results: Prevalence of filarial antigenemia was significantly less in sepsis patients as compared to controls
suggesting that pre-existing filariasis could influence development of sepsis. On the other hand, levels of circulating
filarial antigen were comparable in severe malaria cases and healthy controls suggesting that development of
severe malaria is independent of pre-existing W. bancrofti infections. Plasma TNF-a, RANTES and antibodies to
recombinant malarial proteins as well as levels of circulating CD4+ CD25high cells were comparable in malaria
patients with or without filarial infections.
Conclusions: These observations imply that successful control of filariasis could have adverse consequences on
public health by increasing the incidence of sepsis, while the incidence of severe malaria may not adversely
increase as a consequence of elimination of filariasis.
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Lymphatic dwelling filarial parasites cause severe mor-
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reproduction in any medium, provided the oradministration (MDA) of albendazole with either DEC
or ivermectin. This has been widely acclaimed to be one
of the successful public health programmes and is
expected to block transmission of filariasis in endemic
countries by 2020 [1].
Sepsis is one of the major causes of mortality around
the world and malaria is considered to be one of the
most severe infectious diseases afflicting the world’s
most impoverished populations. Severe malaria presents
itself with a range of biological dysfunctions, i.e. anemia, re-
spiratory complications, acidosis, renal failure, pulmonarytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Development of sepsis and severe malaria share a common
biology with activation of uncontrolled inflammatory host
responses being the cellular and molecular basis for clinical
manifestation. Both diseases are associated with elevated
plasma levels of TNF-a, IL-6, IL-1β, etc. [3,4]. TNF-a is pro-
duced and released by host cells following exposure to vari-
ous malarial antigens. The increase of TNF-a release is
responsible for the overexpression of adhesion molecules,
hence influencing sequestration of parasitized RBCs [5].
Similarly RANTES (Regulated on Activation Normal T-
Cell Expressed and Secreted) is a chemokine involved in
the generation of inflammatory infiltrates. Recent studies
indicate that degradation of cell-cell junctions, blood–brain
barrier dysfunction, recruitment of leukocytes and Plasmo-
dium-infected erythrocytes and occlusion of microvessels
are associated with RANTES expression. Additionally, acti-
vated lymphocytes, platelets and endothelial cells release
large quantities of RANTES, suggesting a unique role for
RANTES in generation and maintenance of the malaria-
induced inflammatory response [6]. Low levels of RANTES
correlate with disease severity and mortality in individuals
with sepsis [7]. However, data on the role of RANTES in
malaria appears to be contradictory. Decreased plasma
levels of RANTES were documented in children with se-
vere malarial anemia [8], but in another study, increased
mRNA expression of RANTES was found in the brains of
children who died of CM [9]. One of the probable reasons
for low levels of RANTES in severe malaria may be the
thrombocytopenia commonly associated with this condi-
tion, as platelets are major reservoirs of RANTES in per-
ipheral circulation [10]. Systemic nematodes on the other
hand are known to down regulate such responses in
infected hosts [11]. This later phenomenon has been attrib-
uted to production of an array of immunomodulatory mol-
ecules released by helminthes that skew host responses
away from a pro-inflammatory phenotype [12]. These ob-
servations suggest that pre-existing helminth infections
could influence development of sepsis or malaria in a given
host. Prevalence of cerebral malaria has been reported to
be low in children with Ascaris lumbricoides infection,
suggesting that endemic subjects harboring helminthic in-
fections could become protected against development of
cerebral malaria [13]. Animal models of sepsis and cerebral
malaria have been used to address the issue, although such
models do not truly represent the human disease. Con-
comitant infection with S. mansoni and P. berghei ANKA
infection has been reported to lead to reduced cerebral
manifestations [14]. More recently, it has been demon-
strated that filarial parasite induced secretion of IL-10 is re-
sponsible for developing resistance to murine cerebral
malaria [15], although this does not appear to be a consist-
ent feature since observations to the contrary have also
been reported [16]. For example, in a study on co-infectionof mice with Litomosoides sigmodontis and P. chabaudi,
mice free of circulating microfilaria were shown to develop
more severe forms of malaria than animals free of microfil-
aria [16].
Here we report a case control study in two cohorts of
patients, one with clinically proven sepsis and the other
with severe P. falciparum malaria and quantified circu-
lating filarial antigen (CFA), to test the hypothesis
whether pre-existing filarial infections could influence
development of severe malaria or sepsis. Insights into
this aspect are of critical public health importance in
predicting possible outcomes of the ongoing successful
filariasis control programme on the incidence of sepsis
or severe malaria in human populations.
Methods
Study area & subject recruitment
Patients with symptoms of sepsis admitted to the De-
partment of Medicine at S.C.B. Medical College were
classified into three categories. 1) Sepsis (n=36): Infec-
tion, documented or suspected, with signs and symp-
toms of an inflammatory response, viz., leukocytosis or
leucopenia, increased C-reactive protein, increased
procalcitonin levels. 2) Severe sepsis (n=24): Sepsis com-
plicated by multi-organ dysfunction. 3) Septic shock
(n=29): Severe sepsis with acute circulatory failure char-
acterized by persistent arterial hypotension despite
adequate volume administration. Details of sepsis
patients are shown in Table 1. For classifying patients
and determining outcomes, the Acute Physiology and
Chronic Health Evaluation II (APACHE II) scoring
system was used [4].
Patients reporting at the out-patient department and/
or admitted to the Department of Internal Medicine at
S.C.B. Medical College (Cuttack, India), with a short his-
tory of fever associated with unarousable coma or multi
organ dysfunction were clinically assessed. Patients with
microscopically demonstrable P. falciparum in thick
blood smears were recruited for the study. Diagnosis
by microcopy was further confirmed by immuno-
chromatographic card test. Details of malaria patients
are shown in Table 2. Non-complicated malaria (NCM)
was defined as patients reporting to the outpatient de-
partment with fever and evidence of P. falciparum infec-
tion. Patients classified with severe malaria belonged to
one of the following three groups:1) Cerebral malaria
(CM, n=48), 2) Non cerebral severe malaria (NCSM,
n=13) and 3) Multi-organ-dysfuction (MOD, n=64) [17].
Thirty-eight normal subjects of comparable ethnicity
and originating from the same areas as that of patients
and free of demonstrable malarial infections were taken
as healthy controls. The current studies on sepsis and
malaria were approved by the Ethics Committee of SCB
Medical College and blood samples were collected after
Table 1 Prevalence of sepsis in filariasis infected subjects
Subjects Sepsis (n=89) Healthy control (n=38) P value
CFA+ve CFA-ve CFA+ve CFA-ve
Number (%) *6 (6.7) 83 (93.3) *16 (42.2) 22 (57.8) CFA+ve in sepsis vs HC (<0.0001), CFA-ve vs in
sepsis vs HC(<0.0001)
Sex(M/F) 6/0 55/28 9/7 10/12 -
Mean Age in years
(range)
42.83(24–73) 46.24(17–85) 31.22(20–75) 29.85(12–69) -
APACHE II score 14.25 ± 4.15 12.63 ± 0.58 - - CFA+ve vs CFA-ve, NS
Mechanical ventillaion 2 (33.34) 7 (8.43) - - CFA+ve vs CFA-ve, NS
Vasopressors 2 (33.34) 18 (21.6) - - CFA+ve vs CFA-ve, NS
Total leukocyte count
(103/mm3)







ND ND CFA+ve vs CFA-ve, NS
NOTE: CFA; circulating filarial antigen.*p value<0.0001, 95% Confidence Interval, Odds ratio = 0.099. Data are no. (%) of participants unless otherwise specified.
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ing persons.
Flow cytometry
About 5ml of the venous blood was collected in heparin
from patients, plasma was separated and frozen at −20°C
until further use. 100 ul of whole blood was used for
two color staining with PE-cy5 labelled anti-CD4 and
FITC labelled anti-CD25 (BD Biosciences), along with ap-
propriate isotype controls. Stained cells were then acquired
on a 2-laser/4 channel BD FACS Calibur Flow Cytometer
and analysed using CellQuest Pro Software.
Enzyme-linked immunosorbent assay (ELISA)
Plasma concentrations of TNF-a and RANTES were
estimated using commercial sandwich ELISA kits
(Sanquin, Amsterdam) according to the manufacturer’s
instructions. Circulating Filarial Antigens (CFA) were
measured by Trop Bio ELISA test kit (Trop Bio Pvt Ltd,
Townsville, Australia) as described earlier by us [18].
Antibodies to malarial recombinant proteins, by solid
phase assay using sporozoite surface protein (SSP-2),
circum-sporozoite protein (CSP), exported antigen AG5.1
(Exp-1) and liver stage antigen-1 (LSA-1) of P. falcipaarum.
Sera were tested after 200 fold dilutions and bound anti-
bodies were detected using 1000-fold-diluted HRP-labeled
anti-human IgG (P0216; Dako) and enzyme activity was
measured using OPD and absorbance read at 492 nm. TheTable 2 Details of study participants
Subjects SM NCM HC
Total number (n) 125 71 38
Sex(M/F) 96/29 47/24 19/19
cp 34(15–72) 30(14–70) 30(12–75)
NOTE: SM Severe malaria1, NCM Non- complicated malaria, HC
Healthy controls.results were expressed as arbitrary ELISA units, using in-
ternal laboratory standards.
Statistics
Statistical analyses were performed by using GraphPad
Prism (version 5.01). For analysis of Figure 1(D and E)
and Figure 2 (A, B, C and D) unpaired student’s t test
was applied to determine differences between groups.
For analysis of Figure 1A, B and Table 1, Fisher-exact
test was employed to calculate Odds ratios (ORs) at 95%
confidence intervals. For analysis of Figure 1C and Figure 3
(B, C, D and E) the association within the groups were
analysed by one way analysis of variance (ANOVA)
followed by Tukey’s post-hoc test. P-values<0.05 were con-
sidered to be statistically significant.
Results
Prevalence of filariasis in sepsis and malaria patients
Prevalence of circulating filarial antigen (CFA) was sig-
nificantly less in patients with sepsis in comparison to
healthy endemic controls (Table 1). While 42.2% of con-
trols were found to harbor CFA, only 6.7% of patients
with sepsis were positive for antigenemia with relatively
low levels of antigenemia (CFA levels of the six CFA+ve
patients were 154, 398, 625, 154, 354 & 542 respect-
ively). These findings suggest that pre-existing filarial
infections could be preventing development of clinical
sepsis (Table 1). On the other hand prevalence of
filarial antigenemia was comparable in severe malaria
patients, non complicated malaria and healthy controls
(Figure 1A). Similarly, the prevalence of filarial
antigenemia was also comparable in three subgroups of
severe malaria i.e. cerebral malaria, non-cerebral severe
malaria and multiorgan dysfunction (Figure 1B). About
45-50% of patients in all the groups were found to har-
bor filarial antigenemia and no statistically significant
Figure 1 Prevalence of circulating filarial antigen, Levels of CFA and levels of plasma cytokines in malaria patients. Number of severe
malaria, non-complicated malaria and healthy control individuals with and without active filarial infection is shown. The sample numbers are SM
(CFA+ve= 69, CFA-ve=56), NCM (CFA+ve=37, CFA-ve=34) and HC (CFA+ve=16, CFA-ve=22). Fisher’s-exact test was employed to compare
percentages between groups (A). Number of cerebral malaria, non-complicated severe malaria and individuals with multiorgan dysfunction with
and without active filarial infection is shown. The sample numbers are CM (CFA+ve= 25, CFA-ve=23), NCSM (CFA+ve=7, CFA-ve=6) and MOD
(CFA+ve=37, CFA-ve=27). Fisher’s-exact test was employed to compare percentages between groups (B). Circulating filarial antigen levels are
comparable in SM (n=125, stars), NCM (n=71, squares) and HC (n=38, circles) cases (C). Association within groups was analysed by one way
analysis of variance (ANOVA) followed by Tukey’s post test. Serum levels of TNF- a (D) and RANTES (E) in CFA +ve and CFA-ve were comparable
in severe malaria, non-complicated malaria and healthy control individuals. Sample numbers for TNF-a: SM (CFA+ve=30, CFA-ve=25), NCM (CFA
+ve=17, CFA-ve=13) and healthy controls (CFA+ve=12, CFA-ve=16). Sample numbers for RANTES: SM (CFA+ve=32, CFA-ve=26), NCM (CFA
+ve=17, CFA-ve=18) and healthy controls (CFA+ve=15, CFA-ve=15). P values were determined by unpaired student’s t-test.
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non-complicated malaria (NCM) and healthy controls,
suggesting that pre-existing filarial infections neither
predispose nor offer resistance for development of
severe malaria. The CFA levels were comparable in the
three categories further validating the above conclusion
(Figure 1C). Similarly, levels of TNF-a as well as
RANTES were also comparable in SM and NCM pa-
tients with and without filarial antigenemia (Figure 1D
and E), suggesting that induction of these inflammatory
molecules in P. falciparum malaria is not influenced by
pre-existing filarial infection. However, TNF-a was sig-
nificantly higher in SM cases in comparison to healthycontrols (data not shown). Significantly higher levels of
RANTES were observed in NCM patients in comparison
to SM patients suggesting their importance during non-
complicated malarial infection (Figure 1E).
Plasma Ab titers against malaria Ags
Specific IgG antibody titers to four different P. falcip-
arum recombinant proteins were quantified in SM,
NCM patients and healthy controls and the data for
SSP-2, CSP, Exp-1 and LSA-1 are shown in Figure 2A, B,
C and D. No significant difference in IgG antibody titers
were observed among CFA+ve and CFA-ve cases of SM,
NCM and healthy controls suggesting that humoral
Figure 2 IgG antibody titers to recombinant malarial antigens in SM, NCM and healthy control individuals. IgG Antibodies to
recombinant malarial proteins SSP-2 (A), CSP (B), Exp-1(C) & LSA-1 (D) among CFA+ve, CFA-ve patients in SM (red, CFA+ve=35, CFA-ve=26), NCM
(blue, CFA+ve=21, CFA-ve=17) and HC (green, CFA+ve=16, CFA-ve=22) as determined by ELISA are shown. Each symbol represents antibody
levels in individual samples and horizontal bars represent the Geometric mean for each group. Students’ unpaired t-test was used to analyze
differences in levels among groups. No significant differences were observed between the three groups.
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significantly altered as a consequence of pre-existing fil-
arial infections. IgG to Exp-1 and LSA-1 was signifi-
cantly low in SM patients in comparison to healthy
controls in CFA+ve and CFA-ve cases (Figure 2C & D).
Similarly IgG to CSP was significantly low in CFA+ve
cases of NCM patients in comparison to CFA+ve cases
of healthy control group (Figure 2B). On the other
hand serum levels of IgG to SSP-2 were significantly
low in SM patients in comparison to healthy controls(Data not shown), but when both the groups were fur-
ther sub-divided as CFA+ve and CFA-ve, a significant
difference was observed only among CFA-ve cases of
both groups. Antibody levels to malarial recombinant
proteins were significantly more in healthy controls in
comparison to patients with acute malaria. Similar ob-
servations of decreased levels of malarial antibodies in pa-
tients have been reported by others [19], which has been
attributed to the presence of circulating malarial antigens
and formation of immune-complexes. IgG subtypes i.e.
Figure 3 Profile of CD4+CD25+ve cells in malaria patients with and without CFA. PBMCs of study subjects at the time of recruitment were
analyzed by flow-cytometry for CD4 and CD25 expression after staining with anti-human CD4-PE.cy5 and anti-human CD25-FITC. Percentage of
CD4+ve T cells expressing CD25 are shown here, A: Zebra plot for CD4+CD25high T–cells, G1 represents CD4+cells, G4 represents CD25+cells, and
G3 represents CD4 + CD25+ cells and G5 represents CD4+CD25 high cells. Percentage of CD4+CD25+ T cells (B) and CD4+CD25high T (C) cells in
SM=91, NCM=58 and control=22 are shown. The association within the groups was analysed by one way analysis of variance (ANOVA) followed
by Tukey’s post-hoc test. Percentages of CD4+CD25+ve T cells and CD4+CD25high T cells in severe malaria (CFA+ve=14, CFA-ve=64), non-
complicated malaria (CFA+ve=13, CFA-ve=34) patients with or without active filarial infection are shown in D and E respectively. The association
within the groups were analysed by one way analysis of variance (ANOVA) followed by Tukey’s post- hoc test.
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may have revealed differences between CFA+ve and –ve
subjects. However, such a possibility could not be tested
due to shortage of malarial recombinant proteins.
CD4+CD25high T cells in the study population with or
without active filarial infection
Filariasis and chronic malaria have been reported to
influence the normal balance of immune-regulatory T
lymphocytes. For this preliminary study CD4+CD25high
cells were regarded as T-regulatory cells and the gating
strategy to score them is shown in Figure 3A [20]. While
scoring CD4+CD25high populations, we also scored CD4
+CD25+ T cells and significantly higher levels of both
the cell populations were observed in NCM cases com-
pared to SM patients (Figure 3B and C). However, when
SM, NCM and healthy controls are analyzed in the con-
text of filarial antigenemia, no significant difference in
levels of this T cell phenotype was observed between the
groups indicating that levels of circulating CD4+CD25+
and CD4+CD25highT cells in malaria patients are not
influenced as a consequence of pre-existing filarial infec-
tion (Figure 3D and E).
Discussion
The primary objective of this case–control study was to
address a critical public health issue viz., what will be
the consequences of an ongoing successful Filariasis
control programme on the incidence of severe malaria
or sepsis in human communities? The study was
conducted in a tertiary hospital in eastern India that re-
ports high incidence of all three diseases. The observa-
tions on incidence of severe malaria vis-à-vis filarial
antigenemia should come as a relief to public health
professionals since the data suggests that incidence of
severe manifestations of P.falciparum malaria such as
cerebral malaria, multi-organ dysfunction etc., may not
adversely increase as a consequence of control/elimin-
ation of filariasis in human communities. These results
do not appear to be in consonance with several co-
infection studies conducted in experimental models of
severe malaria and nematode infections such as L.
sigmodontis [16], H. polygyrus [21] or B. pahangi [15].
Co-infection experiments conducted in animals, how-
ever, need to be interpreted with caution since a) animal
models of cerebral malaria are not considered as truly
representative of severe malaria in humans [22], b) use
of genetically defined strains of mice do not reflect gen-
etic heterogeneity observed in human populations and
more importantly c) such studies do not factor-in epi-
genetic parameters and other common variables ob-
served in human communities.
Our finding on significantly low prevalence of sepsis
in subjects with filarial antigenemia suggests thatdevelopment of clinical sepsis (a hyperinflammation
state) is prevented by pre-existing chronic filarial infec-
tions. This is analogous to another report in the litera-
ture in which prevalence of chronic inflammatory
diseases such as type1 diabetes was less frequent in sub-
jects who were positive for filarial antigenemia [23]. Re-
cently we also reported absence of filarial antigenemia in
rheumatoid arthritis patients living in filarial endemic
areas [24]. These observations give credence to our earl-
ier proposal that circulating filarial antigens bind to
TLR-4 and block activation of human monocytes by
endotoxin. We have also previously demonstrated that a
filarial glycoprotein activates murine macrophages and
human monocytes in vitro in a non-inflammatory path-
way and also blocks development of endotoxemia in
mice. LPS failed to activate PBMCs of subjects with ac-
tive filarial infection as shown by significantly low levels
of synthesis and release of inflammatory cytokines
in vitro [25]. A somewhat similar scenario has been
reported in human Schistosomiasis also further
suggesting that systemic nematode infections could be
offering resistance to hosts from developing clinical sep-
sis [26]. The above studies are further supported by a
paper published by Hubner et al. in Litomosoides
sigmodontis, which suggests that adult worms suppress
LPS induced endotoxemia [27]. However, since the
population in the studied region is covered by the MDA
programme of DEC and albendazole, it is possible that
the infected patients are positive only for antigenemia
(CFA) and not for microfilaraemia and thus are
protected from sepsis. It has been widely proposed that
as a consequence of significant decrease or elimination
of infectious diseases in economically developed coun-
tries there has been an increase in incidence of allergy
and autoimmune diseases over the last century [28].
Low prevalence of filarial antigenemia in sepsis patients
observed in this study tends to support the notion that
increased incidence of sepsis in developed nations dur-
ing the last 100 years could be due to elimination of
metazoan pathogens in these countries. If this is true the
results of the current study suggest that success of the
Global drive for filariasis elimination could have adverse
consequences by way of increasing incidence of sepsis.
Validation of this conclusion is an urgent requirement
and emphasizes the need to undertake similar investiga-
tions on filarial infections in sepsis patients in other geo-
graphical locations and to arrive at a clearer and more
conclusive portrait of the consequences of elimination of
filariasis. The current study, however, has two minor
limitations; a) prevalence of geo-helminthic infection,
which might influence severity of malaria, was not
scored due to non-availability of stool samples from co-
matose patients or from sepsis patients in ICUs. How-
ever, the prevalence of soil transmitted helminthes in
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on Scaling up Treatment of Soil Transmitted Helminthiasis
in the South-East Asia Region, 2011(26) a WHO report on
a survey of soil transmitted helminthes in India, which
shows the prevalence rates from 0.5% to 42% between 1999
to 2003. b) circulating microfilaria could not be quantified.
Both these limitations were due to ethical as well as prac-
tical considerations since patients in ICUs cannot be
subjected to nocturnal blood or stool sample collection.
However, the second issue is not very critical since circulat-
ing microfilaria are rapidly eliminated by single annual
MDA which does not influence antigenemia, taken as a
basis of filariasis in the current study.
Conclusions
The above study suggests that incidence of severe mal-
aria may not adversely increase as a consequence of
filariasis elimination programme in human communities.
Furthermore a significantly low prevalence of sepsis in
subjects with filarial antigenemia was observed which
suggests that development of clinical sepsis (a
hyperinflammation state) is prevented by pre-existing
chronic filarial infections.
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